SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

NCT07855900 on ClinicalTrials.gov · last registry update 2026-10-02

Registered but not yet open, with 350 participants planned. Due to report 25 June 2028, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Percent change in body weight from baseline to Week 52. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status: NOT_YET_RECRUITING
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Boehringer Ingelheim
Sponsor type: Industry
Enrollment: 350
Started: 2026-11-07
Primary completion: 2028-06-25 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-10-02	First seen in registry	Registered as NOT_YET_RECRUITING, P3

Primary outcome

Percent change in body weight from baseline to Week 52

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.